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Abstract
Adrenocortical carcinoma (ACC) is a rare aggressive malignancy with a poor outcome 
largely due to limited treatment options. Here, we propose a novel therapeutic approach 
through modulating intracellular free cholesterol via the liver X receptor alpha (LXRα) in 
combination with current first-line pharmacotherapy, mitotane. H295R and MUC-1 ACC 
cell lines were pretreated with LXRα inhibitors in combination with mitotane. In H295R, 
mitotane (20, 40 and 50 µM) induced dose-dependent cell death; however, in MUC-1, this 
only occurred at a supratherapeutic concentration (200 µM). LXRα inhibition potentiated 
mitotane-induced cytotoxicity in both cell lines. This was confirmed through use of the 
CompuSyn model which showed moderate pharmacological synergism and was indicative 
of apoptotic cell death via an increase in annexinV and cleaved-caspase 3 expression. 
Inhibition of LXRα was confirmed through downregulation of cholesterol efflux pumps 
ABCA1 and ABCG1; however, combination treatment with mitotane attenuated this 
effect. Intracellular free-cholesterol levels were associated with increased cytotoxicity in 
H295R (r2 = 0.5210) and MUC-1 (r2 = 0.9299) cells. While both cell lines exhibited similar 
levels of free cholesterol at baseline, H295R were cholesterol ester rich, whereas MUC-1 
were cholesterol ester poor. We highlight the importance of LXRα mediated cholesterol 
metabolism in the management of ACC, drawing attention to its role in the therapeutics 
of mitotane sensitive tumours. We also demonstrate significant differences in cholesterol 
storage between mitotane sensitive and resistant disease.
Introduction
Adrenocortical carcinoma (ACC) is a rare, aggressive 
malignancy with an incidence of 2–5 per million and 
which carries a poor prognosis due to local invasion or 
distant metastases at the time of diagnosis in the majority 
of cases (Fassnacht et  al. 2013, Libe 2019). Complete 
surgical resection (R0) is the only curative therapy 
(de Reynies et  al. 2009, Kerkhofs et  al. 2013). Yet, for 
those on whom R0 resection is achieved, disease recurs in 
50–85% (Pommier & Brennan 1992, Terzolo et al. 2007). 
Mitotane is the only currently licensed pharmacotherapy 
for adjuvant use or for recurrent disease and remains 
the most effective drug (alone or in combination with 
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platinum based chemotherapy regimens) in preventing 
and treating recurrence (Haak et  al. 1994, Terzolo et  al. 
2007, 2013, Fassnacht et  al. 2018). Mitotane’s use is 
limited by its narrow therapeutic window, whereby at 
serum concentrations below 14 mg/L, it demonstrates 
poor efficacy, while at concentrations >20 mg/L, it is 
associated with unacceptable toxic effects (Hermsen et al. 
2011, Terzolo et al. 2013). There is significant clinical need 
to improve the therapeutic options in managing persistent 
or recurrent ACC, and in this context, the current study 
investigates therapeutic strategies to enhance the efficacy 
and tolerability of mitotane.
Mitotane has been used for 50 years in the 
management of adrenocortical neoplasm (Montgomery & 
Welbourn 1965), yet its adrenotoxic mechanism remains 
incompletely understood (Hescot et  al. 2013, Lehmann 
et  al. 2013, Poli et  al. 2013). Sbiera et  al. demonstrated 
that mitotane-induced adrenotoxicity is associated with 
intracellular free-cholesterol (FC) accumulation causing 
endoplasmic reticulum (ER) stress (Sbiera et  al. 2015). 
The authors also demonstrated that mitotane-induced 
FC accumulation is associated with inhibition of sterol-
O-acyltransferase-1 (SOAT1) which usually converts FC to 
inert cholesteryl esters (CE) for intracellular storage. The 
adrenal-cytotoxic effects of SOAT1 inhibition have also 
been demonstrated by LaPensee et  al. through the use 
of the selective inhibitor ATR-101 (LaPensee et al. 2016). 
Consequently, this lipotoxic mechanism mediated by 
intracellular FC accumulation is considered significant 
or even predominant in terms of mitotane-induced 
adrenotoxicity.
We theorised that the lipotoxic effects of mitotane on 
ACC cells could be enhanced by targeting complementary 
mechanisms to that of SOAT1 inhibition, which would 
further increase intracellular FC. Liver X receptor alpha 
(LXRα/NR1H3) inhibition represents one such mechanism. 
LXRα is a nuclear receptor, sensitive to intracellular FC and 
represents the predominant transcriptional mechanism 
mediating reverse cholesterol transportation to the liver 
(Costet et al. 2000, Kennedy et al. 2005, Wang et al. 2007). 
At rest, LXRα is bound to its nuclear response element 
and held in an inactive state by co-repressor molecules. 
Upon ligand activation, it recruits co-activator proteins 
to dimerise with the retinoid X receptor (RXR), and in 
turn transcribes regulatory proteins for cholesterol efflux, 
namely ABCA1 and ABCG1. These deliver excessive 
intracellular FC to circulating apolipoprotein (Apo) A1 or 
high density lipoprotein (HDL1) (Janowski et al. 1996, Fu 
et al. 2001, Hu et al. 2003, Huuskonen et al. 2004, Phelan 
et al. 2008).
LXRα is highly expressed in liver, innate immune 
cells and adrenal cortex (Cummins et  al. 2006) and its 
sensitivity to intracellular cholesterol is effected through 
endogenous ligand molecules, oxysterols, generated 
from precursor cholesterol. The common oxysterol, 
27-hydroxycholesterol (27HC, also known as (25R)26-HC), 
is catalysed by CYP27A1 and highly expressed in the 
adrenal cortex (Chen et  al. 1998, Fedorova et  al. 2015). 
Higher intracellular FC results in increased oxysterol 
production, activating LXRα dependent transcription 
of cholesterol efflux pumps. The cholesterol regulatory 
function of LXRα is conserved across cell types, mediating 
reverse cholesterol transport as well as providing cellular 
protection against toxic FC accumulation (Cignarella 
et al. 2005, Engel et al. 2007).
In the adrenal, oxysterols and LXRα also have a 
tissue-specific role, whereby they increase steroidogenesis 
by upregulating steroidogenic acute regulatory (StAR) 
protein (Cummins et  al. 2006, Nilsson et  al. 2007). In 
breast and prostate cancer, LXRα stimulation facilitates 
cancer cell survival which is partially explained by its role 
to enhance aerobic glycolysis, while also hypothesised 
to reduce FC-induced cytotoxicity (Nelson et  al. 2013, 
Flaveny et al. 2015, Kim et al. 2018).
We hypothesised that inhibition of LXRα-modulated 
cholesterol efflux pump expression could potentiate 
mitotane-induced lipotoxic adrenocortical cell death 
at usually subtherapeutic mitotane concentrations. We 
investigated the dose-dependent interactions of mitotane 
with pharmacological inhibition of LXRα and dominant-
negative (DN) interference of LXRα activity in two human 
ACC cell lines (H295R and MUC-1). Using this strategy, 
we demonstrate an enhanced ability of mitotane in 
combination with LXRα inhibition to kill ACC cells at 
lower concentrations than for mitotane alone. We show 
that this effect is associated with higher intracellular FC 
accumulation.
Materials and methods
Cell culture and treatments
H295R human primary ACC cells (NCI-H295R, 
CRL-2182; (American Type Culture Collection)) (Rainey 
et  al. 1994) were maintained in DMEM/F12 (Thermo 
Fisher), containing 2.5% Nu serum (Corning), 1% ITS+ 
(Corning), 1% penicillin/streptomycin. H295R cells 
were isolated from a primary adrenocortical tumour of 
a 48-year-old black female and are mitotane sensitive. 
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MUC-1 human metastatic ACC cells were established 
by Hantel et  al. (2016) and maintained in DMEM 
Advanced (Thermo Fisher) containing 5% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. Originally 
isolated from a neck metastasis of a 24-year-old male, 
MUC-1 cells are an aggressive, mitotane resistant model 
of ACC. HepG2 human hepatocellular carcinoma cells 
(HB-8065™; (American Type Culture Collection)) were 
utilised as a comparator cell line and maintained in 
Eagle’s MEM (Thermo Fisher), containing 5% FBS, 1% 
penicillin/streptomycin (Di et  al. 2012, Bruschi et  al. 
2019). Cells were grown in a humidified atmosphere 
containing 5%CO2 and 37°C, used between passage 3–10 
(H295R/HepG2) or passage 21–26 (MUC-1). H295Rs were 
obtained from ATCC (July 2017) and cells are routinely 
tested for steroid production, forskolin responsiveness 
and cell line characteristics.
Pharmacological treatments
Cells were treated at the indicated concentrations of 
GSK2033-LXRα antagonist (Bio-techne, Minneapolis, MN, 
USA) (Griffett & Burris 2016), SR9243-LXRα inverse agonist 
(Flaveny et al. 2015), 27-hydroxycholesterol-endogenous 
LXRα agonist (Enzo Life Sciences), T0901317-synthetic, 
non-steroidal LXRα agonist and mitotane (2,4′-DDD). 
Cells were cholesterol loaded by preparing supplemented 
media using 45 µg/mL water-soluble cholesterol methyl-
β-cylodextrin. All drugs were prepared in DMSO and the 
vehicle control remained below 0.1% at all times. H295R 
cells were pretreated with GSK2033 (5 µM), SR9243 (1 µM) 
or 27HC (5 µM) for 18 h followed by mitotane (20, 40, 
50 µM) for 6 h. MUC-1 cells were pretreated with SR9243 
(5 µM) for 24 h followed by mitotane (50, 100 and 
200 µM) for 24 h. Both cell lines were cholesterol loaded 
1 h prior to mitotane treatment. Reagents were obtained 
from Sigma unless otherwise indicated.
Plasmids, transfection and luciferase assay
H295R were transfected using Lipofectamine 3000 (Thermo 
Fisher) using either pCMX-hLXRα dominant-negative 
(LXR-DN) or WT (LXR-WT) expressing plasmids(Willy et al. 
1995). Transfection efficiency was evaluated using green 
fluorescent protein co-expression (pmaxGFP, Lonza) using 
microscopy and flow cytometry (Supplementary Fig. 1I and 
J, see section on supplementary materials given at the end 
of this article). H295R were transfected in antibiotic free 
media for 24 h prior to drug treatments. Luciferase assay 
was carried out using firefly (pGL3-TK-LXRRE-Luc) and 
renilla luciferase vectors (10:1). Activity were measured 
following 24-h stimulation with LXRα agonist T0901317 (1 
µM) using the Dual-Glo Luciferase Assay System (Promega) 
according to the manufacturer’s guidelines. Luminescence 
was recorded on the Synergy HT Multi-Detection Microplate 
Reader (BioTek), normalised for renilla luciferase activity 
and represented as relative light units (RLU).
Gene expression
Following drug treatments, cells were washed with 
cold phosphate buffered saline (PBS) and total RNA 
was extracted from adherent cells using TRI Reagent®. 
Following spectrophotometric quantification, 1 μg of total 
RNA was reverse transcribed into cDNA using the Qiagen 
RT2 first strand kit. PCR assay was carried out using Go Taq® 
Green Master Mix (Promega), according to manufacturer’s 
guidelines. Amplified products were separated using a 4% 
agarose gel, visualized using SYBR Safe (Thermo Fisher) 
stain and imaged using the ChemiDoc™ XRS+ Imaging 
system (Bio-Rad Laboratories). Real-time quantitative PCR 
expression was assayed on Applied Biosystems StepOne 
Plus (Applied Biosystems) and carried out using SYBR 
green mastermix (Promega). Primer sequences are listed in 
Supplementary Table 1. Fold change was calculated using 
the ΔΔCT method. Data is represented as fold change of 
mRNA relative to vehicle control.
Western blotting
Samples were harvested on ice and lysed using radio-
immuno-precipitation (RIPA) buffer and 1X protease 
inhibitor cocktail (Calbiochem). Lysates were quantified by 
BCA assay, denatured at 95°C and separated by SDS-PAGE 
using a 10% Tris-glycine gel. Proteins were transferred to 
PVDF membrane, blocked using 5% milk and incubated 
with relevant antibodies. Membranes were incubated with 
primary antibodies overnight at 4°C followed by relevant 
HRP-linked secondary antibodies (Supplementary Table 
2). Imaging was carried out using the ChemiDoc™ XRS+ 
Imaging system (Bio-Rad Laboratories) with SuperSignal™ 
HRP substrate (Thermo Fisher) and Image Lab™ Software 
(Bio-rad, V5.2.1). Semi-quantitative densitometry was 
carried out using ImageJ and normalised to the loading 
control (β Actin).
Cell death and apoptosis
H295R were grown as described and stained with 
Calcein AM (Invitrogen) (1 μM) and propidium iodide 
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(PI) (5 μg/mL) to assess viability via microscopy, all 
images (10×) were taken using the EVOS® Cell Imaging 
System (Thermo Scientific). For quantitative analysis, 
cells were trypsinised and resuspended in FACS buffer 
(PBS, 1% FBS, 0.05% sodium azide) following treatment. 
AnnexinV:FITC (Bio-Rad) staining was carried out at 
10 μL/106 cells for 30 min, followed by 5-min PI staining. All 
fluorochromes were excited using a 488 nm laser followed 
by 530/30 (AnnexinV:FITC) and 585/35 (PI) bandpass 
filter. Compensated flow cytometry was performed on 
FACS CantoII® with FACS DiVa 6.0® acquisition software 
(BD Biosciences) and FlowJo® V10 analysis software (Tree 
Star Inc., Ashland, OR, USA). Gating strategy is described 
in Supplementary Fig. 2. AnnexinV and PI positive cells 
are represented as % cells relative to vehicle control.
Metabolic activity assay
MTT assay was carried out in 96 well plates, cells were 
seeded at 1 × 103 cells per well and grown for 3, 7, 10 and 
14 days. Drug treatments GSK2033 (5 μM) and SR9243 
(1 μM) were given at the indicated time points (day 0, 
3, 7 and 10) for 24 h followed by mitotane (50 μM) for 
24 h. Following incubation, MTT reagent (0.5 mg/mL) 
was added. The assay was terminated by solubilising 
MTT using DMSO and absorbance was read at 570 nm 
as described previously. Experimental conditions were 
carried out in replicates of six and the experiment was 
repeated four times. Data is represented as % metabolic 
activity adjusted to matched vehicle control (100%) for 
each individual time point.
Cholesterol analysis
Filipin complex III (Sigma) from Streptomyces filipinensis 
was used to assess free cholesterol (Hassall & Graham 1995). 
Filipin is a fluorescent marker of FC that is excited by a 
405-nm laser followed by a 450/50 bandpass filter. Cells 
were treated as indicated, harvested via trypsinisation and 
fixed using fixation buffer (BioLegend, San Diego, CA, 
USA) according to manufacturer’s guidelines. Staining 
was carried out at 1 mg/mL for 1 h at 4°C in darkness and 
analysed by microscopy and flow cytometry. CholEsteryl 
BODIPY™ FL C12 (cholesteryl 4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoate) 
(Invitrogen) was used to label cholesterol esters (Hsieh 
et al. 2012). Cells were grown to 60% confluence and media 
was supplemented with 5 µM CholEsteryl BODIPY™ FL 
C12 overnight. Cells were harvested via trypsinisation 
and analysed by flow cytometry on the BD FACSCantoII 
(BD Bioscience). Sytox blue (Invitrogen) (1 µM) was used 
as a viability dye. Fluorescence was recorded using a 
488-nm excitation laser followed by a 530/30 bandpass 
filter (CholEsteryl BODIPY™ FL C12) and a 405-nm laser 
followed by 450/50 bandpass filter (Sytox Blue). Single, 
live cells were gated according to Supplementary Fig. 6 
and the resolution metric was calculated as described 
(Brando & Sommaruga 1993). Additionally, cells were 
analysed via imaging flow cytometry using the Amnis® 
ImageStream®xMk II (Luminex Corporation, Seattle, WA, 
USA). High sensitivity mode (60×) was used to record 3500 
events per sample. Analysis was carried out using IDEAS® 
software (V6.2) and, briefly, focused cells were gated 
according to Gradient RMS_M01_Ch01 (<50). Single cells 
were gated using Area_M01 vs Aspect Ratio_M01 (size 
vs circularity). Live cells were gated by using Sytox Blue 
(Invitrogen) viability dye according to Intensity_MC_
Ch07. The population of live, single, focused cells was used 
for analysis of CholEsteryl BODIPY™ FL C12 according 
to Intensity_MC_Ch02. Image display properties were 
standardised as follows: X Range (37, 563), Midpoint 
(300, 127) and X-Axis Scale (32, 568).
Data analysis
Drug synergism was evaluated using CompuSyn (download 
from www.compusyn.com) according to the Chou–Talalay 
method (Chou 2008). Data were input as single agent and 
combined (non-constant ratio) agents as mean ±s.e.m. 
Pharmacological synergism was interpreted according 
to the combination index (CI) model. CI plots and data 
tables are available in Supplementary Fig. 1K, L and M. 
Linear regression and statistical analyses were performed 
using GraphPad® Prism V 8.0 (GraphPad Software). Data 
is represented as mean ± s.e.m. unless stated otherwise. 
Paired sample analyses were performed using a two-sided 
Student’s t-test. Multiple-group comparisons were carried 
out using an ANOVA followed by Tukey’s post-hoc test. 
Statistical significance for two-tailed analyses (P-value) 
was assigned for values <0.05.
Results
LXRα inhibition combined with mitotane enhances 
ACC cell death and significantly reduces ACC cell 
metabolic activity, when compared to mitotane alone
Mitotane produced dose-dependent cytotoxicity in H295R 
in line with previous findings (15, 27 and 28) (Fig. 1A  
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and Supplementary Fig. 1A) with maximally observed 
adrenocortical cell death occurring at the therapeutic 
concentration of 50 μM (16 mg/L) (Fig. 1A). For the 
mitotane-resistant ACC cell line MUC-1, significant 
cell death was observed only at the supratherapeutic 
concentration of 200 μM mitotane (64 mg/L) (Fig. 1C 
and Supplementary Fig. 1D). Consistent with previous 
findings, cell death in MUC-1 (49.1%, mitotane 200 μM) 
was significantly lower than that observed for H295R 
(66.2%, mitotane 50 μM) (Hantel et al. 2016).
Co-treatment of H295R with LXRα inhibitors 
(GSK2033 (5 μM) or SR9243 (1 μM)) and mitotane 
significantly increased cell death at subtherapeutic 
mitotane concentration of 20 μM (16% (mitotane) 
vs 39% (GSK2033 + mitotane), P < 0.0001; 27% 
(SR9243 + mitotane), P = 0.0308). This effect was also 
present for co-treatment of either agent with 40 μM 
mitotane (32% (mitotane) vs 52% (GSK2033 + mitotane), 
P < 0.0001; vs 47% (SR9243 + mitotane) P = 0.0006) and with 
50 μM mitotane co-treated with SR9243 (66% (mitotane), 
76% (SR9243 + mitotane); P = 0.0194) (Fig. 1A and B). 
For MUC-1, LXRα inhibition with SR9243 only increased 
ACC cell death at mitotane 200 μM (46% (mitotane) vs 
69% (SR9243 + mitotane), P < 0.0001) (Fig. 1C).
A time-course experiment demonstrated significantly 
reduced cell metabolic activity of H295R and MUC-1 in the 
presence of 50 μM mitotane alone or in combination with 
LXRα inhibitors (Fig. 1D, E and Supplementary Table 3). 
This effect was greater in H295R and reached significance 
at day 3 in H295R (18% (mitotane), P < 0.0001; 15% 
(GSK2033 + mitotane), P < 0.0001; 9% (SR9243 + mitotane) 
P < 0.0001) and at day 7 in MUC-1 (72% (mitotane), 
P < 0.0001; 58% (GSK2033 + mitotane), P < 0.0016; 
60% (SR9243 + mitotane), P < 0.0089).
We validated these findings of pharmacological 
LXRα inhibition by transfecting H295R cells with a LXRα 
dominant-negative construct (LXRα-DN, transfection 
efficiency: 40%) that blocks LXRα-WT functioning 
(Supplementary Fig. 1G, H, I and J). LXRα-DN-expressing 
cells reached significantly higher rates of mitotane-
induced cytotoxicity for all mitotane concentrations, 
compared to LXRα-WT (11% (WT:mitotane 20 μM) vs 
Figure 1
(A) Graphical representation of percentage cell death using pharmacological inhibitors of LXRα, GSK2033 (5 μΜ) and SR9243 (1 μΜ) to potentiate mitotane 
killing in H295R as quantified by flow cytometric analysis and (B) microscopy. (C) Graphical representation of percentage cell death using SR9243 (5 μΜ) 
to potentiate mitotane killing in MUC-1 as quantified by flow cytometric analysis. Graphical representation of percentage metabolic activity of (D) H295R 
and (E) MUC-1 following GSK2033 (5 μΜ) and SR9243 (5 μΜ) alone and in combination with 50 μΜ mitotane at day 3, 7, 10 and 14, as quantified by MTT 
assay and adjusted to matched vehicle control. (F) Graphical representation of percentage cell death following transfection with LXRα dominant negative 
(LXR-DN) vs LXRα WT (LXR-WT) in combination with mitotane in H295R cells. (G) Graphical representation of percentage dead cells following 27HC 
treatment in combination with mitotane in H295R. Viability data represented as percentage dead cells relative to vehicle control. Metabolic activity data 
represented as percentage cells relative to vehicle control (adjusted to 100% at each respective time point). All data shown as mean ± s.e.m., n = 4. 
Statistical significance is denoted as *P < 0.05, **P < 0.01, ***P < 0.01 and ****P < 0.001 relative to vehicle control or as otherwise indicated.
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24% (DN:mitotane 20 μM), P = 0.0044; 27% (WT:mitotane 
40 μM) vs 53% (DN:mitotane 40 μM), P < 0.001; 55% 
(WT:mitotane 50 μM) vs 67% (DN:mitotane 50 μM), 
P = 0.0089)) (Fig. 1F). These findings suggest an LXRα-
mediated mechanism of enhanced mitotane-induced 
cytotoxicity. We validated these results by stimulating 
LXRα activity using the endogenous ligand oxysterol 
27HC. 27HC reduced mitotane-induced cytotoxicity 
in H295R at concentrations between 10 and 40 μM 
(32% (mitotane) vs 27% (mitotane + 27HC 10 μM), 
P = 0.265; vs 15% (mitotane + 27HC 20 μM), P = 0.0002; vs 
8% (mitotane + 27HC 40 μM), P < 0.0001) (Fig. 1G).
Pharmacological inhibition of LXRα alone with 
GSK2033 or SR9243 reduced cell metabolic activity in both 
cell lines and this effect was similar across all timepoints 
(Fig. 1D and E). LXRα inhibition using GSK2033 but not 
SR9243 had a moderately induced dose-dependent cell 
death in H295R but not MUC-1 (Supplementary Fig. 1B, 
C, E and F). We calculated the combination index (CI) 
using CompuSyn to investigate cytotoxic mechanistic 
synergy between mitotane and LXRα inhibition. SR9243 
demonstrated CI values <1.0, indicative of modest 
synergy with mitotane for its cytotoxic effects in H295R 
across all doses (0.7 (SR9243 + mitotane 20 μM); 0.95 
(SR9243 + mitotane 40 μM); 0.64 (SR9243 + mitotane 
50 μM); 0.59 (GSK2033 + mitotane 20 μM); 0.86 
(GSK2033 + mitotane 40 μM); 0.84 (GSK2033 + mitotane 
50 μM)) and for MUC-1 at mitotane 200 μM only 
(0.81 (SR9243 + mitotane 200 μM)) (Supplementary Fig. 
1K, L and M).
The early apoptosis marker AnnexinV increased dose-
dependent for all mitotane concentrations in the presence 
and absence of GSK2033 or SR9243 in H295R (Fig. 2A). 
The combination of mitotane with GSK2033 resulted in 
higher AnnexinV expression vs 40 μM mitotane alone 
(32% (mitotane 40 μM) vs 50% (GSK2033 + mitotane 40 
μM), P = 0.0004). Combination with SR9243 demonstrated 
higher AnnexinV expression vs all mitotane alone 
(10% (mitotane 20 μM) vs 26% (SR9243 + mitotane 
20 μM), P = 0.0008; 32% (mitotane 40 μM) vs 53% 
(SR9243 + mitotane 40 μM), P < 0.0001; 52% (mitotane 50 
μM) vs 67% (SR9243 + mitotane 50 μM), P = 0.0008). The 
late apoptosis marker, cleaved caspase 3, was also increased 
for mitotane at doses of 40 μM and 50 μM, reflective of 
the higher cell death at these mitotane concentrations. 
Higher cleaved-caspase 3 expression was present for the 
combination with either LXRα inhibitor vs 40 μM or 50 
μM mitotane alone (Fig. 2B and Supplementary Fig. 3A, B). 
There was also higher expression of the ER stress markers 
CHOP and XBP1S/U in mitotane-treated H295R across all 
concentrations, which increased in combination with 
either LXRα inhibitor (Fig. 2C).
For MUC-1, higher cell death at 200 μM mitotane was 
also reflected in higher expression of AnnexinV, which in 
turn was significantly higher with LXRα inhibition with 
SR9234 (3% (VehicleControl) vs 22.6% (mitotane 50 μM), 
Figure 2
(A) Graphical representation of percentage 
AnnexinV positive cells showing an increase in 
apoptosis following GSK2033 (5 μΜ) or SR9243 (1 
μΜ) alone and in combination with mitotane 
treatment in H295R as quantified by flow 
cytometric analysis. (B) Western blotting image 
represents procaspase-3, cleaved caspase-3 and β 
actin expression following GSK2033 (5 μΜ) or 
SR9243 (1 μΜ) alone and in combination with 
mitotane treatment in H295R. (C) Electrophoresis 
gel image representing XPB1unspliced, XBP1spliced, 
CHOP and β actin mRNA expression following 
GSK2033 (5 μΜ) or SR9243 (1 μΜ) alone and in 
combination with mitotane treatment in H295R. 
(D) Graphical representation of percentage 
Annexin V positive cells showing an increase in 
apoptosis in SR9243 (5 μΜ) vs mitotane alone in 
MUC-1 as quantified by flow cytometric analysis. 
Western blot image is representative of three 
independent experiments. Data are represented 
as mean ± s.e.m. (n = 4), statistical comparisons 
were performed using two-way ANOVA followed 
by Tukey’s post-hoc analysis. Statistical 
significance is denoted as *P < 0.05, **P < 0.01, 
***P < 0.01 and ****P < 0.001 relative to vehicle 
control or as otherwise indicated.
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P < 0.0001; 22.6% (mitotane 50 μM) vs 39% (SR9243 
mitotane 50 μM), P < 0.0001)) (Fig. 2D).
LXRα inhibition reduces expression of cholesterol 
efflux pumps in H295R and MUC-1 ACC cells
In H295R and MUC-1, LXRα expression at baseline (Fig. 
3A and B) was equivalent to expression in the positive 
control HepG2 hepatocellular carcinoma cells. Similarly, 
high expression levels of the oxysterol synthetic enzyme 
CYP27A1 were detected (Fig. 3A and B). Transfection 
with a luciferase construct under the control of an 
LXRα-responsive element (TK-LXRRE-Luc) showed 
significant constitutive baseline activation of LXRα, 
which was increased by stimulation with the LXRα 
agonist T0901317 (1 μM) (Fig. 3C). These data indicate 
high activity of the LXRα/oxysterol pathway in adrenal 
cells, equivalent to that of hepatic tissue.
Expression of LXRα target genes, the FC efflux pumps, 
ABCA1 and ABCG1, were reduced by each LXRα inhibitor 
in H295R and MUC-1, respectively (Fig. 3D, E, F, G 
and Supplementary Fig. 4A, B, C, D). In line with these 
findings, expression of ABCA1 and ABCG1 increased in 
both cell lines when stimulated using the non-steroidal 
Figure 3
(A) Western blot images demonstrating protein expression of LXRα and (B) CYP27A1 in H295R, MUC-1 and HepG2 cell lines relative to β actin. (C) 
Graphical representation of luciferase activity in relative luciferase units (firefly/renilla) at baseline and following LXRα agonist T0901317 (1 μM) 
stimulation in transient transfected H295R cells with TK-LXRRE-Luc as reporter assay and a renilla luciferase control plasmid. (D) Graphical representation 
of ABCA1 and (E) ABCG1 mRNA expression as fold change relative to vehicle control following GSK2033, SR9243 and T0901317 stimulation in H295R and (F 
and G) MUC-1. (H) Graphical representation of ABCA1 and ABCG1 mRNA expression as fold change relative to WT transfected vs LXRα dominant-negative 
(DN) transfected H295R. (I) Graphical representation of ABCA1 and (J) ABCG1 mRNA expression as fold change relative to vehicle control (VC) following 
GSK2033 (5 μM) and SR9234 (1 μM) treatment alone and in combination with mitotane in H295R. Western blot image is representative of three 
independent experiments. Data are represented as mean ± s.e.m. (n = 4), statistical comparisons were performed using a two-tailed t-test or a two-way 
ANOVA followed by Tukey’s post-hoc analysis. Statistical significance is denoted as *P < 0.05, **P < 0.01, ***P < 0.01 and ****P < 0.001 relative to vehicle 
control or as otherwise indicated.
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LXRα agonist T0901317 (Fig. 3D, E, F and G). Expression 
for ABCA1 and ABCG1 also decreased in the presence 
of the LXRα-DN construct (Fig. 3H), confirming direct 
involvement of LXRα in their expression.
The responses of ABCA1 and ABCG1 in the presence 
of increasing concentrations of mitotane did not 
significantly change (Fig. 3I and J). However, the efficacy 
of GSK2033 or SR9243 to reduce ABCA1 and ABCG1 
expression were attenuated with mitotane treatment in 
a dose-dependent manner, which is unlikely to reflect 
a direct effect of mitotane on cholesterol efflux pumps. 
However, this may be explained by increasing intracellular 
FC accumulation at higher mitotane doses. We next 
investigated intracellular cholesterol within this model.
LXRα inhibition enhances mitotane-induced toxic 
accumulation of free cholesterol in H295R ACC cells
Mitotane exposure resulted in a dose-dependent increase 
in intracellular FC in H295R, reaching significance at all 
mitotane concentrations (Fig. 4A) (15, 16). The inhibition 
of LXRα with GSK2033 and SR9243 significantly increased 
intracellular FC in H295R at baseline and in combination 
with mitotane, with higher levels for each dose of 
mitotane vs mitotane alone (Fig. 4A and Supplementary 
Fig. 5A). For MUC-1, only the cytotoxic 200-μM mitotane 
concentration resulted in a significant increase in 
intracellular FC, increased further with SR9243 (Fig. 4B). 
Cell death and intracellular cholesterol correlated for 
both cell lines: H295R (r2 = 0.5210, P = 0.008) and MUC-1 
(r2 = 0.9299; P = 0.0001) (Supplementary Fig. 5B and C). 
While intracellular FC differed in response to mitotane 
and LXRα inhibition, baseline levels were similar for 
H295R and MUC-1 (Fig. 4C and D). Interestingly, 
intracellular lipid droplet storage of CE was undetectable 
in MUC-1, when compared to H295R (Fig. 4E, F, G and 
Supplementary Fig. 6A, B).
We next evaluated mitotane-induced cytotoxicity, in the 
presence and absence of LXRα inhibition, for each cell line 
under cholesterol-loaded cell culture conditions. Cholesterol 
Figure 4
(A) Graphical representation of FC (filipin fluorescence), quantified by flow cytometry following combination treatments in H295R and (B) MUC-1. (C) Flow 
cytometry histograms demonstrating baseline FC (filipin fluorescence) levels in H295R and MUC-1 relative to respective unstained control. (D) Graphical 
representation of FC resolution metric in H295R and MUC-1. (E) Flow cytometry histograms demonstrating baseline cholesteryl ester fluorescence in 
H295R and MUC-1 relative to respective unstained control. (F) Graphical representation of cholesteryl ester resolution metric in H295R and MUC-1 cells. 
(G) Representative images (60×) of H295R and MUC-1 of brightfield and cholesteryl ester fluorescence captured via Amnis ImageStream® Imaging Flow 
Cytometry. (H) Graphical representation of percentage dead cells following combination treatments in the presence of cholesterol (45 μg/mL), inset graph 
indicating percentage death in the presence and absence of cholesterol in H295R and (I) in MUC-1. Data are represented as mean ± s.e.m. (n = 3), statistical 
comparisons were performed using a two-tailed t-test or a two-way ANOVA followed by Tukey’s post-hoc analysis. Statistical significance is denoted as 
*P < 0.05, **P < 0.01, ***P < 0.01 and ****P < 0.001 relative to vehicle control or as otherwise indicated. Images are representative of approx. 2000 
focused, single, live cells.
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loading alone induced a moderate but significant increase 
in percentage cell death for both H295R (2% (baseline) 
vs 15% (cholesterol loaded), P < 0.001) and MUC-1 (3% 
(baseline) vs 20% (cholesterol loaded), P = 0.0068) when 
compared to non-loaded cell culture conditions. Treatment 
with each LXRα inhibitor resulted in a two-fold increase 
in H295R cell death in cholesterol-loaded cells. When 
combined with mitotane, both pharmacological LXRα 
inhibitors demonstrated significantly higher cell death for 
subtherapeutic doses of mitotane, with maximally observed 
cell death at 40 μM (12.4 mg/L) (Fig. 4H). Cholesterol loading 
of MUC-1 resulted in an increased cell death at 100 μM and 
200 μM mitotane (7% (baseline mitotane 100 μM) vs 
19% (cholesterol-loaded mitotane 100 μM), P < 0.011) and 
200 μM (46% (baseline mitotane 200 μM) vs 62% 
(cholesterol-loaded mitotane 200 μM), P < 0.003)). The LXRα 
inverse agonist SR9243 only significantly increased cell 
death when combined with mitotane at 200 µM (Fig. 4I).
SOAT1 expression was significantly reduced by 
mitotane at doses <40 µM in H295R (Supplementary Fig. 
5D). However, SOAT1 expression was unaffected by LXRα 
inhibition alone in both cell lines (Supplementary Fig. 
5E and F), suggesting that intracellular FC is increasing 
due to the alternative mechanism of reduced efflux pump 
expression (Fig. 3).
Discussion
Adrenocortical carcinoma (ACC) has demonstrated 
resistance to most cytotoxic chemotherapeutic 
approaches, with mitotane representing the single best 
pharmacotherapeutic for disease control; however, with 
a limited therapeutic window. Recent work demonstrated 
the putative adrenotoxic mechanism of mitotane through 
inhibition of the enzyme SOAT1, resulting in intracellular 
FC accumulation and suggests SOAT1-specific inhibitors 
as stand-alone therapy or adjuncts to mitotane in the 
management of ACC (Sbiera et  al. 2015, LaPensee et  al. 
2016). In the study presented herein, we explored 
LXRα/cholesterol efflux pathway and proposed this as a 
complementary mechanism to enhance toxic intracellular 
FC accumulation in ACC. We investigated these effects 
on two validated in vitro models of ACC: H295R cells 
which are mitotane-sensitive and MUC-1, a metastatic, 
mitotane-insensitive cell line (Hantel et al. 2016).
Transcellular cholesterol flux in steroidogenic cells, 
such as ACC, is central to cellular function and cholesterol 
provides the principle substrate for steroidogenesis. In 
steroidogenic cells intracellular cholesterol (1) is stored 
within lipid droplets following conversion to cholesteryl 
esters by SOAT1 (Cignarella et al. 2005, Dove et al. 2006); (2) 
provides a substrate for steroidogenesis following transfer 
to the mitochondrion via the STAR protein (Stocco & Clark 
1996) or (3) is removed from the cells by the cholesterol 
efflux pumps, ABCA1 or ABCG1 to circulating ApoA1 and 
HDL1, respectively (Kraemer 2007). Cholesterol efflux is 
tightly regulated by the oxysterol/LXRα system through 
conversion of surplus FC to oxysterols through the action 
of enzymes such as CYP27A1. In the adrenal, the role of 
LXRα and its ligand oxysterols are of key relevance in all 
of these processes. This was highlighted by Cummins et al. 
who demonstrated the contribution of oxysterol/LXRα to 
(1) regulate steroidogenesis, (2) control adrenocortical 
cholesterol metabolism and (3) act as a ‘safety valve’ 
through the ABCA1/ABCG1-mediated efflux pathway, 
to provide a basal protective mechanism in preventing 
free-cholesterol induced adrenal lipotoxicity (Cummins 
et al. 2006).
Our data show that pharmacological inhibition 
or functional blockade of LXRα significantly reduced 
cholesterol efflux pump expression (ABCA1 and 
ABCG1) and is accompanied by higher intracellular FC 
concentrations, ER stress, apoptosis and cell death markers. 
Using the combined therapeutic approach, the mitotane-
sensitive H295R underwent apoptosis and cell death at 
subtherapeutic mitotane concentrations. However, MUC-1, 
while combined mitotane/LXRα inhibition considerably 
enhanced the cytotoxic effect of mitotane alone, retained 
their resistance to pharmacologically acceptable mitotane 
concentrations below 200 µM. In both cell lines, higher 
intracellular FC levels were associated with increased 
cell death and when challenged with a cholesterol-
loaded extracellular environment, the cytotoxic effect 
of mitotane alone and in combination with LXRα 
inhibition was further enhanced. These findings support 
our overarching hypothesis and are also in line with 
the findings of other groups (Sbiera and La Pensee) who 
have investigated SOAT1 inhibition (Sbiera et  al. 2015, 
LaPensee et  al. 2016). While H295R were very sensitive 
to combined LXRα/mitotane treatment and MUC-1 
demonstrated enhanced sensitivity to the combination at 
high mitotane doses, MUC-1 gave disappointing results 
in terms of a therapeutic strategy. However, when taken 
together, we believe our data convincingly support a 
role for LXRα and cholesterol storage/efflux in ACC cell 
adaptation and survival.
It is unclear why MUC-1 are insensitive to LXRα/
mitotane treatment. MUC-1 were derived from a metastatic 
neck lesion in a young, mitotane-resistant patient and 
https://doi.org/10.1530/ERC-20-0031
https://erc.bioscientifica.com © 2020 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 04/08/2021 10:35:47AM
via University of Cambridge




for whom four cycles of combination chemotherapy 
were unsuccessful in limiting the extent disease spread. 
When we evaluated intracellular cholesterol in MUC-1, 
we demonstrated an almost complete absence of stored 
cholesteryl esters (CE) at baseline and even under 
cholesterol-loaded conditions (data not shown). In 
contrast, mitotane-sensitive H295R supported a rich 
CE store within their intracellular lipid droplets under 
baseline and cholesterol-loaded culture conditions. Yet, 
in spite of markedly different intracellular CE stores, 
intracellular FC was similar for both cell lines. The 
difference in intracellular cholesterol handling between 
MUC-1 and H295R is interesting, particularly in the 
context of the putative mechanism of mitotane activity 
through SOAT1. We did not perform a SOAT1 activity 
assay; however, the reduced storage of CE in MUC-1 in 
the presence of similar FC suggests low baseline SOAT1 
activity, irrespective of the expression of this enzyme. 
This also suggests that, in contrast to H295R, MUC-1 favor 
alternative mechanism(s) of regulation and clearance of 
intracellular cholesterol, providing a possible escape 
mechanism from mitotane-induced lipotoxicity. Seidel 
et al. have described similar findings in relation to FC and 
CE handling in a strain of HAC15 with induced resistance 
to mitotane (Seidel et  al. 2020). Detailed evaluation of 
lipid/cholesterol metabolism in ACC, using the full range 
of cell lines and banked tumour samples, is necessary 
to evaluate the significance for development of future 
therapeutic strategies.
In the presence of increasing FC accumulation, 
higher mitotane doses attenuated the inhibitory effect of 
LXRα blockade on cholesterol efflux pump expression in 
H295R. In our study, mitotane alone had no significant 
effect on either ABCA1 or ABCG1 expression. Sbeira et al. 
previously demonstrated a short-lived decrease in ABCG1 
which quickly increased back to baseline with prolonged 
therapy (Sbiera et  al. 2015). It is therefore unlikely that 
this is a direct pharmacodynamic effect of mitotane. It is a 
possible secondary effect of intracellular FC accumulation 
which is a substrate for catalysis to 27HC by CYP27A1 and 
will compete with the LXRα antagonists. In line with this 
observation, we have also demonstrated that stimulating 
LXRα with 27HC reduces the therapeutic efficacy of 
mitotane. Whether or not this represents a mechanism 
whereby ACC cells can overcome long-term susceptibility 
to mitotane needs more detailed investigation.
The role of LXRα in supporting the cancer 
microenvironment and promoting cancer cell 
survival is established in other human cancer models 
(Kim et al. 2018, Wang et al. 2019). Higher tumour grade and 
enhanced metastasis in breast cancer have been associated 
with higher LXRα expression and activation (Nelson 
et  al. 2013). Work by Flaveny et  al. also demonstrated 
that the LXRα inverse agonist SR9243 induced apoptosis 
across models of lung, colon and prostate cancer (Flaveny 
et al. 2015). Other work has demonstrated the potential 
for LXRα inhibition to induce lipotoxicity through FC 
accumulation (Schuster et al. 2002, Bradley et al. 2007).
We propose that, based on our date, the use of LXRα 
inhibitors can be translated into a therapeutic strategy for 
mitotane-sensitive ACC by adopting a complementary 
approach to one of mitotane’s known mechanisms 
of action: intracellular FC-induced lipotoxicity. We 
show that enhanced FC accumulation within H295R in 
response to LXRα blockade increased the cytotoxicity of 
mitotane at half the usual minimum therapeutic dose. 
The main limitations to mitotane’s clinical use are (1) no 
significant improvements in progression or recurrence-
free survival of disease below 14 mg/L (Terzolo et  al. 
2013, Berruti et al. 2017) and (2) poor patient tolerability, 
with significant impact on quality of life and inability 
to continue therapy above 20 mg/mL (Haak et al. 1994). 
Recent data have suggested that adjunctive mitotane 
should continue indefinitely even in individuals with 
R0 resection without tumour recurrence (Berruti et  al. 
2017). Therefore, the development of strategies to 
facilitate the long-term tolerability of this drug is an 
important clinical consideration. In relation to mitotane-
resistant disease, we demonstrated increased cell death 
for MUC-1 in response to combined mitotane and LXRα 
inhibition, but show that mitotane-resistance was not 
overcome. Therefore, while adopting this combination 
strategy offers promise in mitotane-sensitive disease and 
to enhance adjuvant mitotane, it is unlikely to be of 
benefit in disease that is mitotane resistant. However, the 
differences in cholesterol handling between mitotane-
sensitive and mitotane-resistant ACC cells demonstrate 
the merits of better understanding the adaptation of ACC 
cells to facilitate metastasis and cell survival. Finally, we 
propose that the selective induction of high cholesterol 
uptake or selective delivery of cholesterol to ACC cells as a 
combination therapy represents an interesting challenge 
for future translational research.
In summary, two cell lines representing some of the 
best validated human cell culture models of ACC, the 
mitotane-resistant metastatic MUC-1 cell line and the 
mitotane-sensitive H295R, representing the standard 
for early mechanistic/therapeutic investigation, were 
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used to investigate LXRα inhibitors and mitotane’s 
effect to induce adrenal cytotoxicity (Rainey et al. 1994, 
Bird et  al. 1995, Wang & Rainey 2012, Hantel et  al. 
2016). Our data suggest a complementary pathway to 
enhance mitotane-induced cytotoxicity by preventing 
FC efflux from ACC cells, mediated through blockade of 
the LXRα pathway and enhanced by cholesterol loading. 
Therefore, it is reasonable to conclude that the mitotane-
LXRα inhibition combined therapeutic approach exploits 
separate but complementary and synergistic mechanisms 
to accumulate toxic levels of FC and to induce ACC 
cytotoxicity. The findings provide valuable mechanistic 
insights and an important backdrop to support further 
animal and pre-clinical studies of the effects of LXRα 
inhibition as a therapeutic target for ACC in mitotane-
sensitive disease. Of the two pharmacological inhibitors 
chosen for investigation, the inverse agonist SR9243 is 
well tolerated in animals and has a favorable toxicity 
profile (Flaveny et  al. 2015, Wu et  al. 2019). This drug 
therefore presents good translational feasibility in 
future in vivo studies. We also highlight the ongoing 
challenge of approaching effective strategies for drug-
resistant metastatic disease and the importance of better 
understanding cholesterol metabolism in ACC cells in 
this regard.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/
ERC-20-0031.
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